HT
CGON icon

Headlands Technologies’s CG Oncology CGON Stock Holding History

Headlands Technologies’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-143
Closed -$4.51K – 1229
2024
Q2 		$4.51K Buy
+143
New +$4.96K ﹤0.01% 1025

Other funds holding CGON

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Headlands Technologies's CGON Position: Q3 2024 in Review

Headlands Technologies sold out of CG Oncology (CGON) in Q3 2024, closing a stake of 143 shares — an estimated $4.51K sold.

Headlands Technologies first reported a position in CGON in Q2 2024 and held it in 1 quarter. The position peaked at $4.51K in Q2 2024. 121 funds tracked by Wall St. Rank hold CGON as of Q3 2024.

  • Headlands Technologies reported no remaining CG Oncology position as of Q3 2024 after selling out during the quarter.
  • Headlands Technologies sold 143 CG Oncology shares in Q3 2024, an estimated $4.51K.
  • Headlands Technologies first reported a position in CG Oncology in Q2 2024 and held it in 1 quarter.
  • Headlands Technologies's CG Oncology position peaked at $4.51K in Q2 2024.
  • 121 funds tracked by Wall St. Rank held CG Oncology as of Q3 2024.

Based on Headlands Technologies's 13F filing for Q3 2024, filed 12 Nov 2024.